Tissue Transglutaminase Test Market Research Report- Forecast till 2030

Tissue Transglutaminase Test Market: By Type (Serological, Biopsy, and others), and By End Users (Hospitals & Clinics, Homecare, Research Organisations, others) - Forecast Till 2030

ID: MRFR/LS/0328-HCR | 81 Pages | Published By Kinjoll Dey on March 2023         

Tissue Transglutaminase Test Market Speak to Analyst Request a Free Sample

Tissue Transglutaminase Test Market Overview

The Tissue Transglutaminase Test Market is expected to reach USD 14,987.6 Million by 2030 at 18.9% CAGR during the forecast period 2022-2030.

Tissue transglutaminase tests are used to identify certain autoimmune diseases, primarily celiac disease. Gluten (an amino acid found in wheat, barley, rye, and oats) is regarded as a foreign invader in celiac disease, and the immune system attacks it. The next step is to produce antibodies directed against the enzyme Tissue Transglutaminase (tTG) (calcium-dependent proteolysis restricting enzyme), which is normally present in the intestines. The antibodies responsible for the autoimmune responses are immunoglobulin A (IgA) and immunoglobulin G (IgG). For diagnostic purposes, the IgA and IgG levels of (tTG) can be analyzed. Because TTG antibody is synthesized in sensitive people's small intestines, where gluten will cause inflammation and irritation, the IgA form is more frequently exploited for celiac disease diagnosis. As an alternative, isotype-matched (tTG) IgG can also be used. When the patient cannot produce normal IgA, its application in testing becomes more obvious since it is less specific to celiac disease. A mucosal biopsy has traditionally been used in celiac disease testing. 

The increasing prevalence of the celiac disease is one of the major factors driving the Tissue Transglutaminase Test Market. World Gastroenterology Organization statistics show that 1% of the population in western countries has been diagnosed with celiac disease. Additionally, celiac disease is becoming more prevalent across regions of the world. From 1998 to 2013, hospitalizations increased by 600% in the U.S., according to the Celiac Disease Foundation. These trends are also observed in Europe. The Tissue transglutaminase test market  will benefit from all of these factors.

COVID-19 Analysis

A worldwide pandemic of COVID-19 has had a significantly negative impact on the way of life. During these times of forced recession, every business must fight both health and economic issues. There are rife speculations that the recovery period could stretch into early next year given the global economic downturn reaching trillions of dollars. 

We believe that companies will benefit greatly from our appropriate insights into the market if we can strategize our way out of this spiral.Market Dynamics

Worldwide the market for Tissue Transglutaminase Test is expanding quickly and the principal justification for this is the expanding frequencies of celiac illness. This illness is profoundly spreading because of gluten (a protein found in wheat, grain, rye, and oats). It is likewise tracked down that celiac sickness spreads because of hereditary qualities. The development of the Tissue Transglutaminase Test market is expanding because of the presentation of DNA tests for HLA markers DQ2 and DQ8 which work on the capacity to distinguish those patients in danger for celiac illness. Practically every one of the patients experiencing celiac infection conveys the HLA markers subsequently there is high development for the Tissue Transglutaminase Test market around the world.

The extending inescapability of resistant framework diseases for the most part celiac ailment, growing the geriatric overall pool, and growing interests in clinical consideration drive the advancement of the market. Low clinical consideration utilization in making districts, costs thoughts, and fake positive examination in geriatric people put aside in light of conditions like free guts, etc to cut off the improvement of the Tissue Transglutaminase Test Market. 

Global geriatric populations, increasing autoimmune diseases, and increased investment in healthcare are driving the Tissue transglutaminase test market growth. The low healthcare expenditure in developing countries, cost considerations, and false-positive diagnoses among the elderly attributed to conditions such as diarrhea hinder the Tissue transglutaminase test market growth. 

Growth Drivers: 

As governments make celiac disease screening more visible, sales of at-home celiac disease testing devices will increase.

Sales of at-home celiac testing kits will increase significantly in the coming years because of product innovations from manufacturers. 

Key Restraints: 

Celiac disease is not well understood and its symptoms are likely to hinder sales.

Technology Analysis

The rapid growth and advancements in technology will lead to the growth of the US market at a global level. Technology is growing and there are multiple ways to do the same tasks, the only difference is in the kind of technology used, which helps to improve the process, speed, or quality of these tests.

Market Segmentation

The Tissue Transglutaminase Test Market has been fragmented dependent on types and end clients and end-users. 

Because of types, the Tissue transglutaminase test market has been sectioned into serological testing, biopsy, and others. The serological testing is sub-fragmented into tissue transglutaminase (tTG) counteracting agent IgA, serum and Tissue Transglutaminase (tTG) neutralizer IgG, serum, and others. 

Given the end clients, the Tissue Transglutaminase Test Market has been sectioned as clinics and facilities, home consideration, research associations, and others. 

In light of types, the Tissue transglutaminase test market has been sectioned into serological, biopsy testing, and others. The serological testing is sub-sectioned into tissue transglutaminase (tTG) counteracting agent IgA, serum, and tissue transglutaminase (tTG) immune response IgG, serum. 

In light of the end clients, the Tissue transglutaminase test market has also been sectioned as emergency clinics and facilities, homecare, research associations, and others.

Regional Analysis

The Americas represent a critical piece of the pie inferable from broad utilization of meds and high consumption of medical care. Furthermore, the quickest take-up of innovation in the US drives the Tissue transglutaminase test market. Likewise, the grouping of significant think-tanks and exploration associations in the created nations of this locale adds fuel to the Tissue Transglutaminase Test Market development. 

Europe is the second-biggest market on the planet because of the big-league salary and high medical services infiltration. 

Asia Pacific area is relied upon to become quickly over the estimated time frame and China and India are probably going to lead Tissue transglutaminase test market because of the quickly developing medical care area. 

Bay countries, for example, Saudi Arabia and the UAE are assessed to drive the Middle East and African market. The African locale is relied upon to observe moderate development inferable from poor financial and political conditions and helpless medical services improvement during the audit time frame.

Competitive Landscape

In the market report for tissue transglutaminase testing, several leading companies are discussed, including Quest Diagnostics Incorporated., SQI Diagnostics, Trinity Biotech, ZEDIRA GmbH, Demeditec Diagnostics GmbH, ARUP Laboratories, Cell Science Systems, and Bio-Rad Laboratories, Inc., Pfizer Inc., Celimmune, LLC., and others. 

This report on Tissue Transglutaminase Test Market includes extensive primary research and a review of key opinions, key opinion leaders, and qualitative and quantitative aspects to gain a deeper understanding of the market and industry dynamics. An extensive analysis of present-day market conditions is offered, which includes past and future market values, volumes, technology advancements, macroeconomic elements, and other factors affecting the market. The report shares key players' strategies as well as detailed information on the market. Also included are detailed breakdowns of the different markets and geographic regions.

Recent Developments

  • In June 2021, Germany-based NanoRepro AG reported the development of its pilot task toward the Western Cape, South Africa, for assembling and dispersion of quick clinical trials for home and clinical use.

  • In June 2021, myLAB Box, a main at-home testing specialist co-op, reported the dispatch of its new Food Sensitivity Test unit. The test offers important experiences into how the client's body will respond to 96 sorts of normal food varieties.¬†


To gain a deeper insight into the market, and industry performance, Market Research Future's report on Tissue Transglutaminase Test provides extensive primary research along with a detailed analysis of both the qualitative and quantitative aspects by various industry experts. An in-depth analysis of the market is provided in this report which covers historical and projected Tissue transglutaminase test market sizes in terms of volume and value, technological advancements, macroeconomics, and governing factors. In the report, the top key players in the industry are detailed and their strategies are outlined. There is also a comprehensive analysis of market segments and regions included in the report. It also gives a detailed analysis for investors to make informed decisions and also analyzes which part of the market will be the most fruitful for an investment decision to be made. The report also skims down the growth and restraints that let us the information on the Tissue transglutaminase Test Market growth. This report is a great opportunity for the Tissue transglutaminase (TTG) Test Market key trends and also a global analysis for Tissue transglutaminase Test Market Value to understand the nitty-gritty of the market.

Report Scope:

Report Attribute/Metric Details
  Market Size   2030: USD 14,987.6 Million
  CAGR   18.9% (2022-2030)
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Quest Diagnostics Incorporated., SQI Diagnostics, Trinity Biotech, ZEDIRA GmbH, Demeditec Diagnostics GmbH, ARUP Laboratories, Cell Science Systems, and Bio-Rad Laboratories, Inc., Pfizer Inc., Celimmune, LLC., and others.
  Key Market Opportunities   Huge investment for research and development in healthcare and strong economic conditions
  Key Market Drivers

  • Increasing prevalence of autoimmune diseases mainly celiac disease
  • Increasing geriatric global pool
  • Increasing investments in the healthcare

  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Tissue tranglutaminase (TTG) test market CAGR would be 18.9% during the forecast period.

    The end users included in the tissue tranglutaminase (TTG) test market report are homecare, research organizations, hospitals & clinics, and others.

    Tissue tranglutaminase (TTG) test market types are serological testing, biopsy, and others.

    Tissue tranglutaminase (TTG) test market report includes players like SQI Diagnostics, Quest Diagnostics Incorporated., ZEDIRA GmbH, Cell Science Systems, Trinity Biotech, ARUP Laboratories, Demeditec Diagnostics GmbH, and Bio-Rad Laboratories, Inc., Pfizer Inc., Celimmune, LLC., and others.

    Europe would be the second-largest tissue tranglutaminase (TTG) test market.